company background image
ADXS

Advaxis OTCPK:ADXS Stock Report

Last Price

US$2.15

Market Cap

US$3.9m

7D

-28.3%

1Y

-94.7%

Updated

24 Sep, 2022

Data

Company Financials
ADXS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ADXS Stock Overview

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States.

Advaxis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Advaxis
Historical stock prices
Current Share PriceUS$2.15
52 Week HighUS$44.80
52 Week LowUS$1.02
Beta2.21
1 Month Change-42.67%
3 Month Change-36.01%
1 Year Change-94.68%
3 Year Change-89.70%
5 Year Change-99.96%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

ADXSUS BiotechsUS Market
7D-28.3%-5.0%-5.2%
1Y-94.7%-30.0%-23.0%

Return vs Industry: ADXS underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: ADXS underperformed the US Market which returned -23.1% over the past year.

Price Volatility

Is ADXS's price volatile compared to industry and market?
ADXS volatility
ADXS Average Weekly Movement15.7%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ADXS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ADXS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200215Ken Berlinhttps://www.advaxis.com

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer.

Advaxis, Inc. Fundamentals Summary

How do Advaxis's earnings and revenue compare to its market cap?
ADXS fundamental statistics
Market CapUS$3.90m
Earnings (TTM)-US$16.24m
Revenue (TTM)US$250.00k

15.6x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADXS income statement (TTM)
RevenueUS$250.00k
Cost of RevenueUS$0
Gross ProfitUS$250.00k
Other ExpensesUS$16.49m
Earnings-US$16.24m

Last Reported Earnings

Jul 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-8.94
Gross Margin100.00%
Net Profit Margin-6,494.80%
Debt/Equity Ratio0%

How did ADXS perform over the long term?

See historical performance and comparison